ym 529 has been researched along with cimadronate in 7 studies
| Studies (ym 529) | Trials (ym 529) | Recent Studies (post-2010) (ym 529) | Studies (cimadronate) | Trials (cimadronate) | Recent Studies (post-2010) (cimadronate) |
|---|---|---|---|---|---|
| 140 | 23 | 71 | 105 | 3 | 4 |
| Protein | Taxonomy | ym 529 (IC50) | cimadronate (IC50) |
|---|---|---|---|
| Farnesyl pyrophosphate synthase | Homo sapiens (human) | 0.1863 | |
| Farnesyl pyrophosphate synthase | Leishmania donovani | 0.16 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burzynska, A; Chan, JM; Colantino, A; Ghosh, S; Kafarski, P; Meints, G; Morita, CT; Oldfield, E; Raker, AM; Sanders, JM; Song, Y; Wang, H | 1 |
| Hall, P; Hudock, MP; Leon, A; Liu, L; Morita, CT; Oldfield, E; Puan, KJ; Studer, D; Yang, Y; Yin, F | 1 |
| Ashihara, E; Hatsuse, M; Hirai, H; Inaba, T; Nakagawa, M; Okamoto, A; Okano, A; Shimazaki, C; Takahashi, R | 1 |
| Iguchi, T; Ikeda, Y; Kizaki, M; Miyakawa, Y; Yamamoto, K | 1 |
| Fushiki, S; Horie, N; Kimura, S; Kubo, T; Maekawa, T; Matsui, T; Murata, H; Nishigaki, Y; Nogawa, M; Segawa, H; Yuasa, T | 1 |
| Kubo, T; Matsuo, T; Ochi, M; Sakai, A; Shimose, S; Tanaka, K; Yasunaga, Y | 1 |
| Imano, M; Itoh, T; Komai, M; Mukai, J; Nishida, S; Ogawa, N; Satou, T; Tsubaki, M | 1 |
7 other study(ies) available for ym 529 and cimadronate
| Article | Year |
|---|---|
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Topics: Alkyl and Aryl Transferases; Animals; Cell Division; Cell Line; Diphosphonates; Geranyltranstransferase; Humans; Leishmania major; Lymphocyte Activation; Models, Molecular; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2004 |
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
Topics: Anti-Bacterial Agents; Cluster Analysis; Diphosphonates; Drug Synergism; Escherichia coli K12; Fosfomycin; Gene Expression; Geranyltranstransferase; Models, Molecular; Oligonucleotide Array Sequence Analysis; Quantitative Structure-Activity Relationship; Terpenes | 2006 |
A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; Diphosphonates; Flow Cytometry; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Tumor Cells, Cultured | 2001 |
Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway.
Topics: Apoptosis; Cell Division; Cell Line, Tumor; Checkpoint Kinase 1; Diphosphonates; Diterpenes; Enzyme Inhibitors; Farnesol; Humans; Imidazoles; Interleukin-6; MAP Kinase Signaling System; Mevalonic Acid; Multiple Myeloma; Phosphorylation; Protein Kinases; S Phase; Signal Transduction; Stromal Cells | 2003 |
The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Diphosphonates; Disease Models, Animal; Drug Screening Assays, Antitumor; GTP-Binding Proteins; Imidazoles; Mice; Osteosarcoma | 2006 |
Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Diphosphonates; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imidazoles; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Sarcoma; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |
Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.
Topics: Alendronate; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bone Density Conservation Agents; Cell Line, Tumor; Cell Nucleus; Cell Survival; Diphosphonates; Gene Expression Regulation, Neoplastic; Gene Silencing; Hematologic Neoplasms; Humans; Imidazoles; MAP Kinase Signaling System; Membrane Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Prenylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Signal Transduction; TOR Serine-Threonine Kinases | 2013 |